Get the Stockscreener App
44.12
1.47%
-0.64
Jyong Biotech Ltd stock is traded at $44.12, with a volume of 5,762.
It is down -1.47% in the last 24 hours and down -8.12% over the past month.
Jyong Biotech Ltd is a science-driven biotechnology company based in Taiwan and is committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia (primarily Taiwan and mainland China). It has been dedicated to the research and development of new drugs with high safety and efficacy. It has been developing a series of drug candidates, including one core drug candidate at NDA stage, one clinical-stage key drug candidate and other preclinical-stage drug candidates.
See More
Previous Close:
$44.76
Open:
$44.19
24h Volume:
5,762
Relative Volume:
0.02
Market Cap:
$3.34B
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-11.80%
1M Performance:
-8.12%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$42.87
$45.00
1-Week Range:
$36.80
$52.01
52-Week Range:
$9.95
$67.00
Jyong Biotech Ltd Stock (MENS) Company Profile
Compare MENS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MENS
Jyong Biotech Ltd
|
43.97 | 3.40B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
423.44 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
636.71 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
441.80 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
824.56 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
181.88 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Jyong Biotech Ltd Stock (MENS) Latest News
Jyong Biotech (NASDAQ:MENS) Shares Gap DownShould You Sell? - MarketBeat
Jyong Biotech (NASDAQ:MENS) Stock Price Up 11.2%Here's What Happened - MarketBeat
FLOWSERVE CORPORATION (FLS) Stock, Price, News, Quotes, Forecast and Insights - MSN
Caterpillar Posts Upbeat Q3 Results, Joins United Therapeutics, Centene, Fortive And Other Big Stocks Moving Higher On Wednesday - Benzinga
Caterpillar, Nvidia Lead Market Cap Stock Movers on Wednesday By Investing.com - Investing.com Nigeria
Caterpillar, Nvidia Lead Market Cap Stock Movers on Wednesday - Investing.com India
Legend Biotech to Host Investor Conference Call on Third Quarter 2025 Results - Yahoo Finance
Jyong Biotech (NASDAQ:MENS) Stock Price Down 15.6%Here's Why - MarketBeat
Tesla and Nvidia lead market cap stock movers this Tuesday - Investing.com
Here's How Much Traders Expect Meta Stock To Move After Earnings This Week - Yahoo Finance
Tesla and Qualcomm Lead Monday’s Market Cap Stock Movers - Investing.com
Tesla and Qualcomm Lead Monday’s Market Cap Stock Movers By Investing.com - Investing.com UK
New Montreal Biotech LifeLore Pathways Launches to Accelerate Microbial Innovation - Yahoo Finance
Jyong Biotech's (MENS) "Sell (E+)" Rating Reaffirmed at Weiss Ratings - MarketBeat
PCI Biotech update - Yahoo Finance
Jyong Biotech (NASDAQ:MENS) Stock Price Up 5.8%What's Next? - MarketBeat
Bitcoin Mining Profitability Declined More Than 7% in September: Jefferies - Yahoo Finance
FDA Grants First CNPV Vouchers, Igniting Rally in Biotech Stocks - Yahoo Finance
Kelun-Biotech Presents Positive Results of Phase 3 Clinical Study OptiTROP-Breast02 for Sacituzumab Tirumotecan in Advanced HR+/HER2- Breast Cancer at 2025 ESMO - Yahoo Finance
KBR Announces Dividend Declaration - Yahoo Finance
UPS To Release Third-Quarter 2025 Results On Tuesday, October 28, 2025 - Yahoo Finance
Jim Cramer on Inspire Medical: “They’ve Had One Execution Issue After Another” - Yahoo Finance
LEIFRAS Co., Ltd. Announces Pricing of Initial Public Offering - Yahoo Finance
Trump Sparks A 2025 IPO Boom: 5 New Stocks Have Rallied Over 400% - Benzinga
Trump Sparks A 2025 IPO Boom: 5 New Stocks Have Rallied Over 400% - Sahm
Jyong Biotech (NASDAQ:MENS) Stock Price Down 4.4%What's Next? - MarketBeat
Q3 Western IPO Activity Centers On US But Offerings Are Rising In The East - Citeline News & Insights
CCTV4: Heritage and Harmony Beneath the Full Moon, The World Is Invited to the CMG 2025 Mid-Autumn Festival Gala - Yahoo Finance
Jyong Biotech (NASDAQ:MENS) Trading 6.5% HigherWhat's Next? - MarketBeat
Eli Lilly, Merck Surge Among Wednesday’s Market Cap Stock Movers - Investing.com
Jyong Biotech (NASDAQ:MENS) Shares Down 8%What's Next? - MarketBeat
RBC Capital Reiterates a Buy Rating on Legend Biotech Corporation (LEGN) - Yahoo Finance
Jyong Biotech Wins Innovation Gold Award in Pharmaceutical Category at 2025 Taipei Biotech Awards - GlobeNewswire
First Taiwan-Developed Botanical Drug in FDA Phase III: Jyong Biotech Wins Gold for BPH Treatment - Stock Titan
The Biotech Stock That's Too Risky for Most Investors - Yahoo Finance
Moleculin Biotech announces issuance of Canadian patent covering Annamycin - Yahoo Finance
Kardigan Advances Late-Stage Portfolio of Personalized Cardiovascular Medicines in Dilated Cardiomyopathy, Acute Severe Hypertension and Calcific Aortic Valve Stenosis - Yahoo Finance
Jyong Biotech (NASDAQ:MENS) Trading Down 6.1%Here's Why - MarketBeat
Kneat Recognised as Leader in G2 Pharma and Biotech Fall 2025 Grid Reports - Yahoo Finance
Tesla and Uber Lead Market Cap Stock Movers on Monday - Investing.com India
MENS Stock Price and Chart — NASDAQ:MENS - TradingView
Jyong Biotech (NASDAQ:MENS) Reaches New 52-Week HighStill a Buy? - MarketBeat
Jyong Biotech (NASDAQ:MENS) Shares Gap UpHere's Why - MarketBeat
Sana Biotechnology Inc. (SANA) Bolsters Management Team - Yahoo Finance
Jyong Biotech Chairwoman and CEO Set to Attend as Speaker at 2025 Global Business Forum in Taipei - GlobeNewswire
Taiwan Biotech Leader Joins Global Business Forum: Jyong CEO to Discuss Cross-Border Innovation - Stock Titan
Jim Cramer Says Apple Inc. (AAPL)’s Going To Have The Best AI - Yahoo Finance
Jyong Biotech (NASDAQ:MENS) Stock Price Down 4.7%Should You Sell? - MarketBeat
Jyong Biotech completes patient enrollment in Phase II trial of MCS-8 - TipRanks
Jyong Biotech Announces Completion of Patient Enrollment of - GlobeNewswire
Jyong Biotech (NASDAQ:MENS) Sets New 12-Month HighHere's Why - MarketBeat
Jyong Biotech Ltd Stock (MENS) Financials Data
There is no financial data for Jyong Biotech Ltd (MENS). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.21%
0.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):